Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;37(3):459-473.
doi: 10.1016/j.idc.2023.03.002. Epub 2023 Mar 22.

COVID-19 Prevention in Solid Organ Transplant Recipients: Current State of the Evidence

Maria Tsikala Vafea  1 , Ghady Haidar  2
Affiliations
Review

COVID-19 Prevention in Solid Organ Transplant Recipients: Current State of the Evidence

Maria Tsikala Vafea et al. Infect Dis Clin North Am. 2023 Sep.

Abstract

Although COVID-19 vaccines are safe, most organ transplant recipients fail to mount an antibody response after two mRNA vaccines. Thus, three mRNA vaccines constitute a primary vaccine series after solid organ transplant. However, neutralizing antibodies after three or greater mRNA vaccines are lower against Omicron versus older variants. Predictors of attenuated responses include age, vaccination within 1 year from transplant, mycophenolate, and BNT162b2. Some seronegative transplant recipients exhibit durable T-cell responses. Vaccine effectiveness in transplants is lower than in the general population. Immunosuppression reduction around revaccination warrants further study. Monoclonal antibody pre-exposure prophylaxis may be protective against susceptible variants.

Keywords: Antibody; COVID-19; SARS-CoV-2; Solid organ transplant; T-cell; mRNA vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Cochran W., Shah P., Barker L., et al. COVID-19 clinical outcomes in solid organ transplant recipients during the omicron surge. Transplantation. 2022;106(7):e346–e347. - PMC - PubMed
    1. Hedvat J., Lange N.W., Salerno D.M., et al. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era. Am J Transplant. 2022;22(11):2682–2688. - PMC - PubMed
    1. Solera J.T., Arbol B.G., Bahinskaya I., et al. Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave. Am J Transplant. 2022 doi: 10.1111/ajt.17199. - DOI - PMC - PubMed
    1. Villamarin M., Marquez-Algaba E., Esperalba J., et al. Preliminary clinical experience of molnupiravir to prevent progression of COVID-19 in kidney transplant recipients. Transplantation. 2022;106(11):2200–2204. - PubMed
    1. Yetmar Z.A., Beam E., O'Horo J.C., et al. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch. Transpl Infect Dis. 2022;24(4):e13901. - PMC - PubMed